Products
Services
Resources
Selection Guides
About
mFluor™ Violet 450 Anti-human CD5 Antibody
UCHT2
UCHT2 is an anti-human monoclonal antibody that is specific for the CD5 antigen. CD5 (sometimes referred to as Tp67) is a 67 kD transmembrane protein that is found on the surface of cells like T cells and B cells. CD5 is involved with essential cellular pathways, for instance, the apoptotic signaling pathway. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands such as CD72, gp35-37, ZAP-70 and TCR. CD5 is a moderately popular antibody target, with over 11000 publications in the last decade. CD5 has been widely used in immunology and costimulatory molecules research, frequently serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to mFluor™ Violet 450 (ex/em = 406/445 nm). It is compatible with the 405 nm laser and 450/50 nm bandpass filter (for example, as in the BD FACSAria™ Fusion).
| Catalog | Size | Price | Quantity |
|---|---|---|---|
| 100520Z0 | 100 tests | Price | |
| 100520Z1 | 500 tests | Price |
Antibody properties
| Other names | Leu1, Ly-1, T1, Tp67 |
| Clone | UCHT2 |
| Host | Mouse |
| Reactivity | Human |
| Application | Flow Cytometry (FACS), Fluorescence Imaging |
Spectral properties
| Absorbance (nm) | 406 |
| Correction factor (260 nm) | 0.338 |
| Correction factor (280 nm) | 0.078 |
| Extinction coefficient (cm -1 M -1) | 35000 1 |
| Excitation (nm) | 406 |
| Emission (nm) | 445 |
| Quantum yield | 0.81 1 |
Usage and storage
| Intended use | Research Use Only (RUO) |
Contact us
| Telephone | |
| Fax | |
| sales@aatbio.com | |
| International | See distributors |
| Bulk request | Inquire |
| Custom size | Inquire |
| Technical Support | Contact us |
| Request quotation | Request |
| Purchase order | Send to sales@aatbio.com |
| Shipping | Standard overnight for United States, inquire for international |
Page updated on August 1, 2026